# Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

> **NCT02049190** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Arno Therapeutics** · enrollment: 75 (estimated)

## Conditions studied

- Prostate Cancer
- Metastatic Prostate Cancer
- Androgen-independent Prostate Cancer
- Recurrent Prostate Cancer

## Interventions

- **DRUG:** onapristone
- **DRUG:** abiraterone

## Key facts

- **NCT ID:** NCT02049190
- **Lead sponsor:** Arno Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-02
- **Primary completion:** 2017-07
- **Final completion:** 2017-12
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2015-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02049190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02049190, "Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02049190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*